Shandong Keyuan Pharmaceutical Co., Ltd. (SHE:301281)
China flag China · Delayed Price · Currency is CNY
48.82
+2.38 (5.12%)
At close: Sep 14, 2026

SHE:301281 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Equivalents
171.69359.08178.13325.22148.9766.01
Short-Term Investments
---210.26--
Trading Asset Securities
70.16-254.43150.54--
Cash & Short-Term Investments
241.85359.08432.56686.02148.9766.01
Cash Growth
-34.36%-16.99%-36.95%360.50%125.69%76.29%
Accounts Receivable
254.81117.9795.8575.8556.8743.71
Other Receivables
12.8612.3227.110.650.310.69
Receivables
267.67130.29122.9676.557.1844.4
Inventory
127.44147.45128.94108.0567.9286.44
Other Current Assets
127.3415.576.268.228.26.53
Total Current Assets
764.3652.39690.73878.79282.27203.38
Property, Plant & Equipment
691.44679.36477314.2308.83290.27
Long-Term Investments
199.59191.52190.31184.08--
Goodwill
1.031.031.82---
Other Intangible Assets
194.55112.74107.1746.0249.0851.76
Long-Term Deferred Tax Assets
5.034.263.062.922.091.62
Long-Term Deferred Charges
2.473.592.390.731.733.15
Other Long-Term Assets
52.6142.7879.9843.227.799.34
Total Assets
1,9111,6881,5521,470651.79559.51

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Accounts Payable
141105.6542.2550.1854.9860.58
Accrued Expenses
12.8749.644.5939.7129.2323.65
Short-Term Debt
82.66-----
Current Income Taxes Payable
15.1401.080-4.59
Current Unearned Revenue
5.916.7720.243.53.023.09
Other Current Liabilities
74.4213.9611.6317.7520.6418.83
Total Current Liabilities
331.99175.99119.78111.14107.86110.75
Long-Term Debt
120.39112.3445.66---
Long-Term Unearned Revenue
11.648.419.2710.539.0410.11
Long-Term Deferred Tax Liabilities
16.7218.2917.7817.2515.167.66
Other Long-Term Liabilities
0.3416.450.38---
Total Liabilities
481.08331.48192.87138.93132.06128.52

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Common Stock
108.29108.29108.29108.295858
Additional Paid-In Capital
919.92907.68907.67909.97195.34195.34
Retained Earnings
394.44335.16340.26312.3266.2174.93
Comprehensive Income & Other
6.884.422.570.480.192.72
Total Common Equity
1,4301,3561,3591,331519.73430.98
Minority Interest
0.410.630.81---
Shareholders' Equity
1,4301,3561,3601,331519.73430.98
Total Liabilities & Equity
1,9111,6881,5521,470651.79559.51

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Total Debt
203.05112.3445.66---
Net Cash (Debt)
38.8246.73386.9686.02148.9766.01
Net Cash Growth
-85.77%-36.23%-43.60%360.50%125.69%76.29%
Net Cash Per Share
0.352.243.586.771.830.81
Filing Date Shares Outstanding
108.28108.29108.29108.2981.281.2
Total Common Shares Outstanding
108.28108.29108.29108.2981.281.2
Working Capital
432.31476.4570.95767.65174.492.64
Book Value Per Share
13.2012.5212.5512.296.405.31
Tangible Book Value
1,2341,2421,2501,285470.65379.23
Tangible Book Value Per Share
11.4011.4711.5411.875.804.67
Buildings
-220.06216.15213.26208.05186.34
Machinery
-373.66342.54316.21275.82210.37
Construction In Progress
-390.16183.1512.1519.9966.23